| Literature DB >> 27587545 |
Vincent Cottin1, Elisabeth Bel2, Paolo Bottero3, Klaus Dalhoff4, Marc Humbert5, Romain Lazor6, Renato A Sinico7, Pasupathy Sivasothy8, Michael E Wechsler9,10, Matthieu Groh11, Sylvain Marchand-Adam12, Chahéra Khouatra13, Benoit Wallaert14, Camille Taillé15, Philippe Delaval16, Jacques Cadranel17, Philippe Bonniaud18, Grégoire Prévot19, Sandrine Hirschi20, Anne Gondouin21, Bertrand Dunogué10, Gérard Chatté22, Amandine Briault23, David Jayne24, Loïc Guillevin25, Jean-François Cordier13.
Abstract
The respiratory manifestations of eosinophilic granulomatosis with polyangiitis (EGPA) have not been studied in detail.In this retrospective multicentre study, EGPA was defined by asthma, eosinophilia and at least one new onset extra-bronchopulmonary organ manifestation of disease.The study population included 157 patients (mean±sd age 49.4±14.1 years), with a mean±sd blood eosinophil count of 7.4±6.4×109 L-1 at diagnosis. There was a mean±sd of 11.8±18.2 years from the onset of asthma to the diagnosis of EGPA, of 1.4±8.4 years from the first onset of peripheral eosinophilia to the diagnosis of EGPA, and of 7.4±6.4 years from EGPA diagnosis to the final visit. Despite inhaled and oral corticosteroid treatment, the severity of asthma increased 3-6 months before the onset of the systemic manifestations. Asthma was severe in 57%, 48%, and 56% of patients at diagnosis, at 3 years, and at the final visit, respectively. Persistent airflow obstruction was present in 38%, 30%, and 46% at diagnosis, at 3 years, and at the final visit, respectively.In EGPA, asthma is severe, antedates systemic manifestations by a mean of 12 years, and progresses to long-term persistent airflow obstruction despite corticosteroids in a large proportion of patients, which affects long-term management and morbidity.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27587545 DOI: 10.1183/13993003.00097-2016
Source DB: PubMed Journal: Eur Respir J ISSN: 0903-1936 Impact factor: 16.671